ZURICH (Reuters) – Roche said on Wednesday a late stage trial for its tiragbolumab drug to treat small cell lung cancer has failed to reach its targets.
The Skyscraper 2 study failed to meet its aim of progression-free survival in patients during a phase III trial, the Swiss company said.
(Reporting by John Revill; Editing by Paul Carrel)
